As of 10:46am ET
| +0.35 / +0.83%|
The 7 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 45.00, with a high estimate of 51.00 and a low estimate of 36.00. The median estimate represents a +5.51% increase from the last price of 42.65.
The current consensus among 7 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.